eprintid: 17883 rev_number: 10 eprint_status: archive userid: 2 dir: disk0/00/01/78/83 datestamp: 2025-12-04 23:32:24 lastmod: 2025-12-04 23:32:25 status_changed: 2025-12-04 23:32:24 type: article metadata_visibility: show creators_name: Bayo Jimenez, Maria T. creators_name: Rivas-García, Lorenzo creators_name: Sánchez-González, Cristina creators_name: Grosso, Giuseppe creators_name: Lipari, Vivian creators_name: Vera-Ramírez, Laura creators_name: Battino, Maurizio creators_name: Giampieri, Francesca creators_name: Quiles, José L. creators_name: Forbes-Hernández, Tamara Y. creators_id: creators_id: creators_id: creators_id: creators_id: vivian.lipari@uneatlantico.es creators_id: creators_id: maurizio.battino@uneatlantico.es creators_id: francesca.giampieri@uneatlantico.es creators_id: jose.quiles@uneatlantico.es creators_id: title: Natural Products in Alzheimer’s Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms ispublished: pub subjects: uneat_bm subjects: uneat_sn divisions: uneatlantico_produccion_cientifica divisions: uninimx_produccion_cientifica full_text_status: public keywords: amyloid; cognitive impairment; dementia; flavonoids; neuroprotection; omega-3 fatty acids; oxidative stress; phenolics; tau abstract: This systematic review included 31 clinical trial articles examining the effects of natural compounds on Alzheimer’s disease (AD) and mild cognitive impairment (MCI), involving 3582 participants aged 50–90. Treatment durations ranged from 8 weeks to 2 years, with an average of 12.5 months. Notably, 11 studies focused on herbal extracts highlighting their prominence in current research. These extracts showed potential cognitive and neuroprotective benefits, although results varied across compounds and study designs. Other natural compounds—including flavonoids, polyphenols, omega-3 fatty acids, Aloe vera, Spirulina, and citrus phytochemicals—may provide cognitive and neuroprotective benefits, with ginseng and Ginkgo biloba combinations also showing promise. Curcumin and Melissa officinalis had limited effects, resveratrol showed mixed outcomes with some side effects, and matcha green tea may improve cognition and sleep quality. Despite generally favorable results, the studies varied considerably in design and quality; nonetheless, herbal extracts represent a prominent category of natural interventions in AD and MCI, underscoring the need for further large-scale, high-quality clinical trials to confirm their therapeutic potential. date: 2025-10 publication: International Journal of Molecular Sciences volume: 26 number: 21 pagerange: 10631 id_number: doi:10.3390/ijms262110631 refereed: TRUE issn: 1422-0067 official_url: http://doi.org/10.3390/ijms262110631 access: open language: en citation: Artículo Materias > Biomedicina Materias > Alimentación Universidad Europea del Atlántico > Investigación > Producción Científica Universidad Internacional Iberoamericana México > Investigación > Artículos y libros Abierto Inglés This systematic review included 31 clinical trial articles examining the effects of natural compounds on Alzheimer’s disease (AD) and mild cognitive impairment (MCI), involving 3582 participants aged 50–90. Treatment durations ranged from 8 weeks to 2 years, with an average of 12.5 months. Notably, 11 studies focused on herbal extracts highlighting their prominence in current research. These extracts showed potential cognitive and neuroprotective benefits, although results varied across compounds and study designs. Other natural compounds—including flavonoids, polyphenols, omega-3 fatty acids, Aloe vera, Spirulina, and citrus phytochemicals—may provide cognitive and neuroprotective benefits, with ginseng and Ginkgo biloba combinations also showing promise. Curcumin and Melissa officinalis had limited effects, resveratrol showed mixed outcomes with some side effects, and matcha green tea may improve cognition and sleep quality. Despite generally favorable results, the studies varied considerably in design and quality; nonetheless, herbal extracts represent a prominent category of natural interventions in AD and MCI, underscoring the need for further large-scale, high-quality clinical trials to confirm their therapeutic potential. metadata Bayo Jimenez, Maria T.; Rivas-García, Lorenzo; Sánchez-González, Cristina; Grosso, Giuseppe; Lipari, Vivian; Vera-Ramírez, Laura; Battino, Maurizio; Giampieri, Francesca; Quiles, José L. y Forbes-Hernández, Tamara Y. mail SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, SIN ESPECIFICAR, vivian.lipari@uneatlantico.es, SIN ESPECIFICAR, maurizio.battino@uneatlantico.es, francesca.giampieri@uneatlantico.es, jose.quiles@uneatlantico.es, SIN ESPECIFICAR (2025) Natural Products in Alzheimer’s Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms. International Journal of Molecular Sciences, 26 (21). p. 10631. ISSN 1422-0067 document_url: http://repositorio.unini.edu.mx/id/eprint/17883/1/ijms-26-10631-v2.pdf